08/01/1993 - "HA-1A, a monoclonal antibody against endotoxin, was thought to be effective in treating patients with Gram-negative sepsis. "
03/01/1997 - "The HA-1A Sepsis Study Group."
04/01/1990 - "Phase I trials will need to be carried out to characterize further the pharmacokinetics and toxicity of HA-1A in patients with gram-negative sepsis."
08/01/1994 - "A total of 543 patients with severe sepsis presumed to be caused by Gram-negative bacteria who were enrolled in a clinical trial to evaluate the efficacy and safety of HA-1A human monoclonal antibody. "
08/01/1994 - "We sought to determine whether there might be acute changes in hemodynamics attributable to HA-1A, a monoclonal antibody to endotoxin, in patients with presumed Gram-negative sepsis. "
|2.||Systemic Inflammatory Response Syndrome (Sepsis Syndrome)
02/13/1993 - "In patients with a Gram-negative bacteraemia the delay between the onset of the sepsis syndrome and the administration of HA-1A was longer (median 22 h versus 14.3 h in the Ziegler study, mean 30 versus 20 h). "
02/13/1993 - "[Cost-effectiveness analysis of human monoclonal antibody HA-1A in patients with sepsis syndrome]."
02/13/1993 - "Evaluation of HA-1A treatment in patients with the sepsis syndrome. "
02/13/1993 - "[Immunotherapy using the anti-endotoxin antibody HA-1A in patients with sepsis syndrome; good results in relation to treatment with placebo]."
02/13/1993 - "HA-1A does not appear to be beneficial in critically ill patients with a longstanding sepsis syndrome, especially not if an intra-abdominal sepsis is apparent. "
08/01/1994 - "There is no apparent relationship between the administration of HA-1A, the presence of Gram-negative bacteremia, and hemodynamic profiles over the 72-hr study period."
08/01/1994 - "Patients were grouped by the study drug, HA-1A, or placebo, and the presence or absence of Gram-negative bacteremia. "
06/13/1994 - "Using criteria for treatment and exclusions from the HA-1A trial, three of the patients with gram-negative bacteremia would have been treated, while at least 52 patients without gram-negative bacteremia might have received HA-1A therapy (positive predictive value of criteria, 5.5%). "
07/01/1991 - "In a major, multicenter, double-blind trial of HA-1A 100 mg administered intravenously versus placebo, mortality was greatly reduced in HA-1A recipients with gram-negative bacteremia. "
12/01/1995 - "One hundred thirty-one patients (43 with gram-negative bacteremia) received HA-1A during a 19-month open-label protocol. "
02/13/1993 - "In comparison with the HA-1A study we selected sicker patients: the mean APACHE II score was higher, 93% of our patients were in shock and 85% had organ failure. "
09/25/1991 - "DATA SYNTHESIS - Direct comparison of E5 and HA-1A antibody studies is difficult because of differences in their design, definitions of shock, and methods of subgroup analysis. "
09/14/1991 - "Monoclonal antibody HA-1A for gram-negative shock."
04/27/1991 - "Monoclonal antibody HA-1A for gram-negative shock."
02/01/1991 - "In contrast to E5, HA-1A protected patients in shock, but only when they were bacteremic at randomization. "
01/01/1991 - "J5 anti-sera, E-5, and HA-1A are all effective in reducing the mortality in patients with gram-negative infections. "
11/14/1994 - "This cohort study did not confirm decreased mortality in patients with GNB bacteremia, as reported in the first placebo-controlled HA-1A trial, and it further suggests excess mortality in the subgroup of patients with non-GNB infection. "
02/01/1993 - "HA-1A human monoclonal antibody reduced mortality in patients with gram-negative infections who were bacteremic or in shock. "
02/13/1993 - "Intensive-care patients with the sepsis syndrome and shock or organ failure with a presumptive diagnosis of Gram-negative infection were eligible for treatment with HA-1A. "
11/14/1994 - "Of 600 patients who received HA-1A in a 1-year period, 75% had documented GNB infection and 39% had GNB bacteremia; 94% had hypotension and 54% had refractory shock. "
|6.||Immunoglobulin M (IgM)
|8.||bactericidal permeability increasing protein
|2.||Intensive Care (Surgical Intensive Care)